<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676633</url>
  </required_header>
  <id_info>
    <org_study_id>SRN-705-005</org_study_id>
    <nct_id>NCT04676633</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, PK, Anti-Tumor Activity of STP705 Injected IT in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy</brief_title>
  <official_title>Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sirnaomics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translational Drug Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sirnaomics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, dose escalation and dose expansion study to evaluate the safety,&#xD;
      tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally&#xD;
      in cholangiocarcinoma, hepatocellular carcinoma or liver metastasis in subjects with&#xD;
      advanced/metastatic or surgically unresectable solid tumors who are refractory to standard&#xD;
      therapy.&#xD;
&#xD;
      Goals:&#xD;
&#xD;
        1. To determine the MTD or RP2D of STP705 when administered intratumorally into&#xD;
           cholangiocarcinoma, hepatocellular carcinoma, or liver metastasis.&#xD;
&#xD;
        2. To establish the dose of STP705 recommended for future phase 2 studies when administered&#xD;
           intratumorally.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, dose escalation and dose expansion study to evaluate the safety,&#xD;
      tolerability, pharmacokinetics, and anti-tumor activity of various doses of STP705&#xD;
      administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma or liver&#xD;
      metastasis.&#xD;
&#xD;
      The primary objective of this study is to determine the MTD or RP2D of STP705 and to&#xD;
      establish the dose of STP705 recommended for future phase 2 studies when administered&#xD;
      intratumorally.&#xD;
&#xD;
      A total of up to 30 patients will be enrolled in the dose escalation phase of the study. In&#xD;
      addition, once the MTD or recommended phase 2 dose has been established, up to 20 additional&#xD;
      patients maybe enrolled to confirm safety and explore anti-tumor activity.&#xD;
&#xD;
      Up to five dose levels will be explored (20,40,80,160,320 μg dose levels) and will depend on&#xD;
      the number and intensity of observed toxicity. Intermediate doses maybe explored during&#xD;
      escalation period.&#xD;
&#xD;
      It will follow an accelerated titration design, enrolling 1 patient per dose cohort and will&#xD;
      expand to a standard 3+3 design after.&#xD;
&#xD;
      In the accelearted titration a Grade 2 SE triggers the transition to the 3+3 part of the&#xD;
      study. The 3+3 part of the study will start at dose level 160μg.&#xD;
&#xD;
      Subjects will be evaluated for DLTs in the first cycle of treatment and graded aacording to&#xD;
      NCI CTCAE v5. A cycle is 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Accelerated titration design followed by expansion to standard 3+3 design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>28 day cycle</time_frame>
    <description>Recommended starting dose &amp; schedule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Limited Dose Toxicity (LTD)</measure>
    <time_frame>28 day cycle</time_frame>
    <description>Recommended starting dose &amp; dose escalation</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver Metastases</condition>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: STP705 20 μg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: STP705 40 μg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: STP705 80 μg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: STP705 160 μg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: STP705 320 μg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STP705</intervention_name>
    <description>Investigational Product</description>
    <arm_group_label>Cohort 1: STP705 20 μg dose</arm_group_label>
    <arm_group_label>Cohort 2: STP705 40 μg dose</arm_group_label>
    <arm_group_label>Cohort 3: STP705 80 μg dose</arm_group_label>
    <arm_group_label>Cohort 4: STP705 160 μg dose</arm_group_label>
    <arm_group_label>Cohort 5: STP705 320 μg dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with histologically or cytologically confirmed advanced/metastatic or&#xD;
             surgically unresectable cholangiocarcinoma, hepatocellular carcinoma, or other solid&#xD;
             malignancy with one or more qualifying liver metastases who are refractory to standard&#xD;
             therapy&#xD;
&#xD;
               -  Have at least one liver tumor or metastasis (≤ 5 cm in size) that is not&#xD;
                  sub-capsular and not near any major blood vessel&#xD;
&#xD;
               -  Have no more than 7 liver lesions&#xD;
&#xD;
               -  Is deemed safe for percutaneous intra-tumoral injection by local radiologist&#xD;
&#xD;
          2. Measurable disease per RECIST v 1.1 (primary or metastatic disease)&#xD;
&#xD;
          3. ECOG performance status or 0 - 1&#xD;
&#xD;
          4. Life expectancy of at least 3 months&#xD;
&#xD;
          5. Age ≥ 18 years&#xD;
&#xD;
          6. Signed, written Institutional Review Board (IRB) approved informed consent&#xD;
&#xD;
          7. A negative serum pregnancy test (for nonsterile women of child-bearing potential)&#xD;
&#xD;
          8. Baseline Q-T corrected interval (QTc) interval of ≤ 480 msec using Frederica's formula&#xD;
&#xD;
          9. Acceptable liver function:&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 times upper limit of normal&#xD;
&#xD;
               -  AST (SGOT), ALT (SGPT) and Alkaline phosphatase ≤ 5 times upper limit of normal&#xD;
                  because of cancer or metastases to the liver&#xD;
&#xD;
         10. Acceptable renal function, defined as:&#xD;
&#xD;
             o Serum creatinine ≤ 1.5 ULN or Creatinine Clearance ≥ 30 mL/minute&#xD;
&#xD;
         11. Acceptable hematologic status:&#xD;
&#xD;
               -  Hemoglobin ≥ 8 g/dL (a transfusion is allowed if Hemoglobin stays stable&#xD;
                  thereafter)&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3&#xD;
&#xD;
               -  Platelet count ≥100,000 plt/mm3 x 109/ L (≥ 65,000 if low platelet counts are due&#xD;
                  to splenic sequestration and portal hypertension)&#xD;
&#xD;
         12. Urinalysis with no clinically significant abnormalities&#xD;
&#xD;
         13. Acceptable coagulation status with partial thromboplastin time (PTT) and International&#xD;
             Normalized Ratio (INR) ≤1.5 times upper limit of normal&#xD;
&#xD;
         14. Subject has adequate vitamin D level, as defined by serum total 25-Hydroxyvitamin D&#xD;
             [25(OH)D] ≥ 20 to &lt; 60 ng/mL&#xD;
&#xD;
         15. Completion of all previous treatments (including surgery, systemic chemotherapy and&#xD;
             radiotherapy), as well as supportive care (including transfusion of blood, blood&#xD;
             components and granulocyte colony-stimulation factor [G-CSF] treatment) at least 3&#xD;
             weeks before screening (6 weeks for nitrosoureas or mitomycin C), with no signs or&#xD;
             symptoms of acute toxicity &gt; Grade 1 (except alopecia)&#xD;
&#xD;
         16. For men and women of child-producing potential, the use of effective contraceptive&#xD;
             methods during the study&#xD;
&#xD;
         17. No aspirin for ≥ 5 days in advance of intra-tumoral administration, as well as&#xD;
             discontinuation of antiplatelet and anticoagulant medications for the appropriate&#xD;
             amount of time&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. New York Heart Association Class III or IV cardiac disease, or myocardial infarction,&#xD;
             severe unstable angina, coronary/peripheral artery bypass graft, congestive heart&#xD;
             failure within the past 6 months&#xD;
&#xD;
          2. Known active, uncontrolled infection with HIV or hepatitis B; patients with hepatitis&#xD;
             B allowed if on anti-viral therapy and have a viral load ≤ 500 IU; patients with a&#xD;
             history of HIV must be on antiretroviral therapy for at least four weeks and have an&#xD;
             HIV viral load ≤ 400 copies/mL, have CD4+ T cell counts ≥ 350 cells/uL and no history&#xD;
             of AIDS-defining opportunistic infections within 3 months prior to treatment&#xD;
&#xD;
          3. Hepatocellular carcinoma patients with a Child Pugh score &gt; B7&#xD;
&#xD;
          4. Had paracentesis in the last 3 months; presence of ascites must be controlled by&#xD;
             diuretics&#xD;
&#xD;
          5. History of hepatic encephalopathy in the last 6 months&#xD;
&#xD;
          6. History of variceal bleeding in the last 6 months&#xD;
&#xD;
          7. Concomitant medications that are strong inhibitors or inducers of CYP450 enzymes that&#xD;
             cannot be stopped or replaced during the study&#xD;
&#xD;
          8. Major surgical procedure within 4 weeks prior to initiation of study treatment, or&#xD;
             anticipation of need for a major surgical procedure during the course of the study.&#xD;
             (Note: Placement of a central venous access catheter(s) (e.g., port or similar) is not&#xD;
             considered a major surgical procedure.)&#xD;
&#xD;
          9. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic&#xD;
             therapy&#xD;
&#xD;
         10. Pregnant or nursing women. NOTE: Women of child-bearing potential and men must agree&#xD;
             to use adequate contraception (hormonal or barrier method of birth control; or&#xD;
             abstinence) prior to study entry and for the duration of study participation. Should a&#xD;
             woman become pregnant or suspect she is pregnant while participating in this study,&#xD;
             she should inform her treating physician immediately.&#xD;
&#xD;
         11. Participation in a clinical study involving administration of an investigational&#xD;
             compound within the past 30 days prior to study entry.&#xD;
&#xD;
         12. Previous intratumoral injection within the past 30 days prior to study entry.&#xD;
&#xD;
         13. Unwillingness or inability to comply with procedures required in this protocol&#xD;
&#xD;
         14. Known allergy or hypersensitivity to the study drug(s) or one of the ingredients in&#xD;
             the formulation&#xD;
&#xD;
         15. Existence of any surgical, medical or laboratory condition that, in the judgment of&#xD;
             the clinical investigator, might interfere with the safety, distribution, metabolism&#xD;
             or excretion of the drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadia Sheibani</last_name>
    <role>Study Director</role>
    <affiliation>Sirnaomics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>nadia sheibani</last_name>
    <phone>301-740-1730</phone>
    <email>nadiasheibani@sirnaomics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Honor Health</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul McKinney</last_name>
      <phone>480-323-3805</phone>
      <email>pmkinney@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Sunil Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mengsha Li</last_name>
      <phone>626-218-0494</phone>
      <email>meli@coh.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Kessler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiomara Menendez</last_name>
      <phone>323-865-0212</phone>
      <email>menendez_x@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony El-Khoueiry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hartford Healthcare</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priyanaka Abraham</last_name>
      <phone>860-972-5018</phone>
      <email>Priyanka.Abraham@hhchealth.org</email>
    </contact>
    <investigator>
      <last_name>Jessica Clement, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine koranyi</last_name>
      <phone>862-881-9131</phone>
      <email>christine.koranyi@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Angela Allistar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katy Schroeder</last_name>
      <phone>414-805-8843</phone>
      <email>kbaxheowswe@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Ben Goeorge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

